UNSPSC 51161702: Beractant

This classification denotes a respiratory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S866O45PIG.The European Medicines Agency schedules Beractant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13043MIG. As of Q4 2014, BERACTANT remains the US FDA Preferred Term for this commodity.

UNSPSC 51161702 Beractant, a Commodity code, does not reflect the actual work state and local governments are currently procuring under this taxonomy entry. The recent opportunities associated with this code span naloxone and drug deactivation systems, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic pharmaceuticals and over-the-counter products — none of which align with beractant, a surfactant used for respiratory distress syndrome in neonates. The code appears to be a data-tagging error within state and local procurement systems rather than a genuine procurement category for beractant itself. No recent solicitations for beractant as a standalone pharmaceutical are present in the source material.

The issuing bodies posting opportunities tagged to this code include county health departments (Seminole County, Florida; Hall County, Georgia), a state health and human services commission (Texas HHS Commission), and a multi-state cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local government facilities including Oregon). Geographic activity centers on Florida, Georgia, Texas, and Minnesota, with the cooperative vehicle extending to additional participating jurisdictions. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023), Hall County's RFQ/P for on-site pharmacy services at a county family health center (RFQ/P #47-010, due June 4, 2026), Texas HHS Commission's RFI on direct-to-manufacturer prescription fulfillment (RFI HHS0017013, April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026). The code shows substantive recent activity, but vendors should clarify actual procurement intent with issuing bodies rather than relying on the beractant classification to identify relevant opportunities.